News
Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...
https://pubmed.ncbi.nlm.nih.gov/31821107/
https://pubmed.ncbi.nlm.nih.gov/31429628/ (Not open access)
https://pubmed.ncbi.nlm.nih.gov/31394429/
https://pubmed.ncbi.nlm.nih.gov/29641567/
https://pubmed.ncbi.nlm.nih.gov/28375678/
https://pubmed.ncbi.nlm.nih.gov/28182673/
https://pubmed.ncbi.nlm.nih.gov/27612288/
https://pubmed.ncbi.nlm.nih.gov/29078406/
Sinnamon et al., Proc Natl Acad Sci USA 2017
https://vicotx.com/sinnamon-et-al-proc-natl-acad-sci-usa-2017/https://pubmed.ncbi.nlm.nih.gov/32668243/
Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...
